Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Lo-Coco F, et al. Among authors: cerqui e. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. N Engl J Med. 2013. PMID: 23841729 Free article. Clinical Trial.
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F. Cicconi L, et al. Among authors: cerqui e. Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2. Leukemia. 2016. PMID: 27133819 Clinical Trial.
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F. Efficace F, et al. Among authors: cerqui e. J Clin Oncol. 2014 Oct 20;32(30):3406-12. doi: 10.1200/JCO.2014.55.3453. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245446 Clinical Trial.
Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.
Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R. Bassan R, et al. Among authors: cerqui e. Leuk Lymphoma. 2019 Dec;60(14):3482-3492. doi: 10.1080/10428194.2019.1639170. Epub 2019 Jul 12. Leuk Lymphoma. 2019. PMID: 31298059 Clinical Trial.
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S. Voso MT, et al. Among authors: cerqui e. Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154. Ann Oncol. 2017. PMID: 28368509 Free article. Clinical Trial.
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.
Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, Finelli C, Cerqui E, Ottone T, Molteni A, Parma M, Santarone S, Candoni A, Sica S, Leone G, Lo-Coco F, Voso MT. Falconi G, et al. Among authors: cerqui e. Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5. Leukemia. 2019. PMID: 30291338 Free PMC article. No abstract available.
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study).
Cattaneo C, Monte S, Algarotti A, Audisio E, Borlenghi E, Campiotti L, Cerqui E, Fanizza C, Giuliani R, Micò C, Rocconi R, Salvi A, Salvi F, Verga L, Levis A, Lambertenghi Deliliers G, Pogliani EM, Tognoni G, Rambaldi A, Rossi G. Cattaneo C, et al. Among authors: cerqui e. J Antimicrob Chemother. 2011 Sep;66(9):2140-5. doi: 10.1093/jac/dkr271. Epub 2011 Jul 5. J Antimicrob Chemother. 2011. PMID: 21729932 Clinical Trial.
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.
Falconi G, Fabiani E, Criscuolo M, Fianchi L, Finelli C, Cerqui E, Pelosi E, Screnci M, Gurnari C, Zangrilli I, Postorino M, Laurenti L, Piciocchi A, Testa U, Lo-Coco F, Voso MT. Falconi G, et al. Among authors: cerqui e. Leuk Res. 2019 Sep;84:106191. doi: 10.1016/j.leukres.2019.106191. Epub 2019 Jul 19. Leuk Res. 2019. PMID: 31386932
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL).
Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Vià M, Ciceri F, Passamonti F, Mancini V, Sciumè M, Cerqui E, Sciumè M, Rossi G. Borlenghi E, et al. Among authors: cerqui e. J Geriatr Oncol. 2021 May;12(4):550-556. doi: 10.1016/j.jgo.2020.10.004. Epub 2020 Oct 20. J Geriatr Oncol. 2021. PMID: 33097455
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G. Malagola M, et al. Among authors: cerqui e. Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715369 Free PMC article.
21 results